Latest News
India develops anti Covid drug for emergency use
May 09, 2021
The Drugs Controller General of India (DCGI) has granted permission for emergency use of anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG), developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Laboratories (DRL),Hyderabad.
In a release issued on Saturday, the Ministry of Defence said that as per the order, emergency use of this drug as adjunct therapy in moderate to severe Covid-19 patients is permitted. It added that being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.
The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique. Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence, noted the release.
It further said that higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid-19 patients. “The drug will be of immense benefit to people suffering from Covid-19,” said the Ministry.(The Hindu)
RELATED NEWS
View all
Latest News
Teenage suspect arrested over Ambalangoda shooting as youth crime concerns grow
Sep 25, 2026
Latest News
Nanayakkara invokes Mark Fernando episode in defence of judicial reforms
Sep 25, 2026
Latest News
New Bill seeks to eliminate rabies and regulate dog ownership in Sri Lanka
Sep 24, 2026
Latest News
Screen time rising among Sri Lankan preschool children, Health Ministry warns
Sep 24, 2026
